<DOC>
	<DOCNO>NCT03069703</DOCNO>
	<brief_summary>The study hypothesis `` reinforce '' pneumococcal combine vaccine strategy patient ANCRA-associated vasculitides treat rituximab induce well immune response current standard regimen , acceptable safety profile . This study therefore aim evaluate immunogenicity safety two `` reinforce '' innovative pneumococcal vaccine regimen [ double quadruple dose 13-valent anti-pneumococcal conjugate vaccine ( PCV13 ) follow one dose 23-valent unconjugated vaccine ( PPV23 ) month 5 ] , compare standard regimen ( one dose PCV13 follow one dose PPV23 month 5 ) , patient ANCA-associated vasculitides receive rituximab therapy .</brief_summary>
	<brief_title>Innovative Anti-pneumococcal Vaccine Strategies Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy</brief_title>
	<detailed_description>Description research methodology Experimental plan This comparative , multicenter , prospective , randomize , open label , phase 2 trial France , compare two innovative `` reinforce '' anti-pneumococcal vaccine strategy standard vaccination regimen patient ANCA-associated vasculitides receive rituximab therapy . Participants randomize 1:1:1 three parallel arm receive : - Arm 1 ( standard vaccination regimen ) : prime-boost strategy combine single dose 13-valent pneumococcal conjugate vaccine ( Prevenar , PCV13 ) Day 0 ( lie within window ± 2 day first infusion rituximab ) , follow single dose 23-valent unconjugated vaccine ( Pneumo 23 , PPV23 ) month 5 ( M5 ) - Arm 2 ( innovative vaccine strategy 1 ) : prime-boost strategy combine 2 dos PCV13 Day 0 2 dos PCV13 Day 7 , follow single dose PPV23 M5 - Arm 3 ( innovative vaccine strategy 2 ) : prime-boost strategy combine 4 dos PCV13 Day 0 , follow single dose PPV23 M5 All participant receive rituximab 375 mg/m2/week 4 consecutive week , Days 0 ± 2 day , Day 7 ± 2 day , Day 14 ± 2 day Day 21 ± 2 day , induction therapy vasculitis flare , follow 500 mg-rituximab infusion every 6 month maintenance therapy , i.e . Month 6 , Month 12 Month 18 ( Stone , NEJM , 2010 , Jones , NEJM , 2010 ; Guillevin , NEJM , 2014 ) , recommend . Day 0 define first vaccine injection ( within ± 2 day first infusion rituximab ) . PCV13 vaccine injection perform Day 0 , Day 7 ± 1 day Arm 2 . PPV23 injection perform M5 ± 7 day arm . Analysis immune response perform centralized laboratory blind trial arm , ELISA Day 0 ( pre-vaccination sample ) , M1 , M5 , M6 , M12 , M18 12 serotypes common conjugate unconjugated vaccine , OPA Day 0 , M6 , M12 , M18 12 serotypes common conjugate unconjugated vaccine , ELISA Day 0 M6 3 specific serotypes PPV23 . Safety monitoring Relevant adverse event related vaccination continuously monitor throughout trial , pause rule specify protocol trigger ad-hoc iDSMB meeting case safety concern Number participate centre This multicenter research involve participation French Vasculitis Study Group ( FVSG ) network , include 100 clinical department involve management ANCA-associated vasculitides . As previous trial conduct FVSG topic , around 50 center participate PNEUMOVAS research . Randomization Participants fulfill eligibility criterion study enrol randomize ratio 1:1:1 three different parallel arm . Randomization stratify : personal history PPV23 injection age ( &gt; &lt; 65 year ) . Blinding method provision put place maintain blind Trial participant site staff blind vaccine arm . The central laboratory perform immunogenicity assessment ( ELISA OPA ) blind trial arm order limit measurement bias .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>1 . Participants diagnosis ANCAassociated vasculitis , particular GPA MPA , accord ACR 1990 criterion and/or revise Chapel Hill Consensus Conference definition and/or European Medical Agency algorithm 2 . Participants ( male female ) age 18 year old 3 . Participants childbearing potential reliable contraception duration study 4 . Participants newlydiagnosed disease time inclusion present relapse disease . For relapse patient , maintenance therapy stable dose last 3 month admit : prednisone dose &lt; 10 mg/day , azathioprine dose &lt; 3 mg/kg/day , methotrexate dose &lt; 25 mg/week , mycophenolate mofetil dose &lt; 3 g/j 5 . Participants active disease define BVAS ≥ 3 6 . Participants plan receive rituximab induction therapy use recommend regimen ( i.e . 375 mg/m2/week 4 consecutive week ) 7 . Participants able give write informed consent prior participation study 8 . Participants cover social security regimen equivalent 1 . Participants eosinophilic granulomatosis polyangiitis vasculitis 2 . Participants thrombocytopenia coagulation disorder 3 . Participants acute infection chronic active infection inclusion visit . 4 . Documented positive serology result HIV , HBV ( Ag Hbs ) , HCV inclusion . 5 . Participants disease associate decrease immune response ( splenectomy , hematopoietic stem cell transplantation , primary immune deficiency common variable immunodeficiency , cancer within previous 5 year , drepanocytosis ) , 6 . Participants treat rituximab within previous 12 month , 7 . Participants receive blood , blood product , and/or plasma derivative include parenteral immunoglobulin preparation past 12 week enrolment , 8 . Participants treat new immunosuppressive immunomodulatory agent within previous 3 month ( include cyclophosphamide , antiTNFalpha , intravenous immunoglobulin , abatacept ) , 9 . Participants treat prednisone dose &gt; 10 mg/day duration great 15 day inclusion , 10 . Participants vaccination conjugate antipneumococcal vaccine time , 11 . Participants vaccination PPV23 within previous 3 year , 12 . Participants receive another vaccine within 4 week prior enrolment plan receive vaccine within first 6 month study ( except annual influenza vaccination permit 4 week vaccination visit study allow time study follow ) 13 . Pregnant woman lactation , 14 . Participants contraindication use rituximab , 15 . Participants contraindication intramuscular injection ( hemophilia , anticoagulant therapy ) 16 . Participants hypersensitivity previous vaccination 17 . Participants hypersensitivity aluminium phosphate , phenol protein CRM197 protein Corynebacterium diphtheria . 18 . Participants include another investigational therapeutic study month prior D0 . Participation observational research allow . 19 . Participants legal guardianship incapacitation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>ANCA- associate vasculitides</keyword>
	<keyword>pneumo 23</keyword>
	<keyword>prevenar</keyword>
	<keyword>pneumovas</keyword>
</DOC>